Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 5/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 7/20 | 0.37 |
| ▸ | CDK9 | P50750 | 7/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | WEE1 | P30291 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 3/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | CCND2 | P30279 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
| ▸ | EIF4EBP1 | Q13541 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451567 | 0.88 | EGFR (0.44) | PTK2CDK2CDK9CCNT1CCNE1 | |
| SCHEMBL3448177 | 0.85 | PTK2 (0.40) | PTK2PTGS2CDK2CDK9CCNT1 | |
| SCHEMBL3452880 | 0.82 | PTGS2 (0.38) | PTK2PTGS2CDK2CDK9CCNT1 | |
| SCHEMBL3345818 | 0.80 | PIM2 (0.43) | PTK2PTGS2CDK2CDK9CCNT1 | |
| SCHEMBL3450788 | 0.79 | IDH1 (0.41) | SYK | |
| SCHEMBL3448896 | 0.78 | SYK (0.39) | SYK | |
| SCHEMBL3452877 | 0.76 | CDK2 (0.40) | CDK2CDK9SYK | |
| SCHEMBL3342145 | 0.73 | CDK2 (0.40) | PTK2CDK2CDK9HDAC3HDAC1 | |
| SCHEMBL3449925 | 0.73 | SYK (0.42) | PTK2CDK2SYK | |
| SCHEMBL3451325 | 0.73 | SYK (0.42) | PTK2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | PTK2 3971/4885PTGS2 355/4885CDK2 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.